Bora Pharmaceuticals Co., Ltd. (BORAY)
OTC Markets OTCQX
Price as at 30 Sept 2026, 16:39 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Bora Pharmaceuticals Co., Ltd. trades at $7.00. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Bora Pharmaceuticals Co., Ltd.
Bora Pharmaceuticals Co., LTD. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services for the development of pharmaceutical products. In addition, it provides Western pharmaceuticals, including central nervous system medications, antibiotics, and gastrointestinal medications; and nutritional and vitamin supplements, physical recovery, and health care products. The company sells its products directly to clinics, pharmacies, pharmacy chains, and drug stores, as well as through distributors to medical centers, corporate and public hospitals, and regional and district hospitals. Bora Pharmaceuticals Co., LTD. was incorporated in 2007 and is based in Taipei City, Taiwan.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its BORAY data?
Fundamentals for BORAY come from company filings and exchange data, as listed on OTC Markets OTCQX; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 16:39 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for BORAY, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.